Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMRNNASDAQ:DYNNASDAQ:TBPHNASDAQ:TYRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMRNAmarin$10.42+0.1%$9.48$7.08▼$19.10$215.79M0.6674,881 shs84,346 shsDYNDyne Therapeutics$12.56+10.1%$10.38$6.36▼$47.45$1.43B1.191.65 million shs4.78 million shsTBPHTheravance Biopharma$8.80-2.0%$9.21$7.44▼$10.90$440.01M-0.1272,787 shs417,517 shsTYRATyra Biosciences$10.26+1.7%$9.62$6.42▼$29.60$544.70M1.17259,682 shs426,700 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMRNAmarin+0.10%-1.70%+12.04%+0.19%-38.89%DYNDyne Therapeutics+9.79%+6.17%+78.41%-7.10%-51.69%TBPHTheravance Biopharma-1.23%-14.48%+4.76%-2.65%-6.18%TYRATyra Biosciences+1.68%-2.29%+28.89%-15.42%-40.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMRNAmarin0.464 of 5 stars1.04.00.00.02.60.00.0DYNDyne Therapeutics3.1481 of 5 stars4.51.00.00.03.23.30.0TBPHTheravance Biopharma1.5808 of 5 stars3.10.00.00.02.42.50.6TYRATyra Biosciences1.6829 of 5 stars3.50.00.00.02.92.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMRNAmarin 2.00Hold$7.00-32.82% DownsideDYNDyne Therapeutics 3.07Buy$46.85272.98% UpsideTBPHTheravance Biopharma 2.25Hold$11.3328.79% UpsideTYRATyra Biosciences 3.00Buy$30.83200.52% UpsideCurrent Analyst Ratings BreakdownLatest TBPH, TYRA, DYN, and AMRN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$46.00 ➝ $38.005/9/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.004/17/2025AMRNAmarinThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$20.00 ➝ $7.003/31/2025TYRATyra BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$30.00 ➝ $30.003/28/2025TYRATyra BiosciencesWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$30.003/21/2025DYNDyne TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$18.00 ➝ $17.003/17/2025DYNDyne TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.003/17/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.003/12/2025DYNDyne TherapeuticsBMO Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$50.003/7/2025DYNDyne TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSector Outperform$50.002/28/2025DYNDyne TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$50.00 ➝ $50.00(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMRNAmarin$228.61M0.94N/AN/A$1.35 per share7.72DYNDyne TherapeuticsN/AN/AN/AN/A$1.49 per shareN/ATBPHTheravance Biopharma$65.27M6.74N/AN/A$4.28 per share2.06TYRATyra BiosciencesN/AN/AN/AN/A$4.74 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMRNAmarin-$59.11M-$3.64N/AN/AN/A-16.33%-7.22%-4.96%N/ADYNDyne Therapeutics-$235.94M-$3.59N/AN/AN/AN/A-57.46%-51.62%N/ATBPHTheravance Biopharma-$55.19M-$1.18N/A25.14N/A-78.18%-24.79%-13.43%N/ATYRATyra Biosciences-$69.13M-$1.63N/AN/AN/AN/A-24.56%-23.31%N/ALatest TBPH, TYRA, DYN, and AMRN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025DYNDyne Therapeutics-$0.88-$1.05-$0.17-$1.05N/AN/A5/8/2025Q1 2025TBPHTheravance Biopharma-$0.11-$0.27-$0.16-$0.27$28.08 million$15.39 million5/8/2025Q1 2025TYRATyra Biosciences-$0.49-$0.47+$0.02-$0.47N/AN/A5/7/2025Q1 2025AMRNAmarin-$0.06-$0.04+$0.02-$0.04$50.75 millionN/A3/27/2025Q4 2024TYRATyra Biosciences-$0.48-$0.43+$0.05-$0.43N/AN/A3/12/2025Q4 2024AMRNAmarin-$1.20-$2.40-$1.20-$0.12$32.37 million$62.31 million3/4/2025Q4 2024DYNDyne Therapeutics-$0.92-$0.88+$0.04-$0.88N/AN/A2/26/2025Q4 2024TBPHTheravance Biopharma-$0.05-$0.31-$0.26-$0.31$29.90 million$18.75 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMRNAmarinN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ATYRATyra BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMRNAmarinN/A3.232.11DYNDyne TherapeuticsN/A17.0217.02TBPHTheravance BiopharmaN/A4.974.97TYRATyra BiosciencesN/A29.5529.55Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMRNAmarin22.25%DYNDyne Therapeutics96.68%TBPHTheravance Biopharma99.10%TYRATyra Biosciences84.14%Insider OwnershipCompanyInsider OwnershipAMRNAmarin3.30%DYNDyne Therapeutics14.14%TBPHTheravance Biopharma6.90%TYRATyra Biosciences15.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMRNAmarin36020.71 million402.62 millionOptionableDYNDyne Therapeutics100113.63 million80.63 millionOptionableTBPHTheravance Biopharma35950.00 million45.78 millionOptionableTYRATyra Biosciences2053.09 million42.81 millionOptionableTBPH, TYRA, DYN, and AMRN HeadlinesRecent News About These CompaniesTyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by BrokeragesMay 13 at 2:09 AM | marketbeat.comTyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPSMay 12 at 5:45 PM | marketbeat.comTyra Biosciences to Participate at Upcoming Investor ConferencesMay 12 at 4:05 PM | prnewswire.comFarallon Capital Management LLC Invests $13.91 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 11 at 7:40 AM | marketbeat.comOne Tyra Biosciences Insider Raised Stake By 284% In Previous YearMay 9, 2025 | finance.yahoo.com54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Acquired by Raymond James Financial Inc.May 9, 2025 | marketbeat.comTyra Biosciences Reports First Quarter 2025 Financial Results and HighlightsMay 8, 2025 | prnewswire.comWhy Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%May 6, 2025 | aaii.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by BVF Inc. ILMay 6, 2025 | marketbeat.comSusquehanna Fundamental Investments LLC Invests $543,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 6, 2025 | marketbeat.com29,100 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Bought by Renaissance Technologies LLCMay 6, 2025 | marketbeat.comComparing Tyra Biosciences (NASDAQ:TYRA) & Mallinckrodt (OTCMKTS:MNKKQ)May 6, 2025 | americanbankingnews.comAlly Bridge Group NY LLC Cuts Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comBoxer Capital Management LLC Buys Shares of 2,027,678 Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comMarshall Wace LLP Acquires 34,463 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)May 4, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Bought by RA Capital Management L.P.May 3, 2025 | marketbeat.comTyra Biosciences (TYRA) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comNantahala Capital Management LLC Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA)April 30, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by JPMorgan Chase & Co.April 28, 2025 | marketbeat.comWalleye Capital LLC Sells 63,617 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA)April 24, 2025 | marketbeat.comTyra Biosciences, Inc. (NASDAQ:TYRA) Given Consensus Recommendation of "Buy" by BrokeragesApril 19, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Is McDonald’s Stock Serving a Value Meal to Investors? By Jeffrey Neal Johnson | April 13, 2025View Is McDonald’s Stock Serving a Value Meal to Investors? Medtronic: A Dividend Aristocrat With Stability and InnovationBy Jeffrey Neal Johnson | April 22, 2025View Medtronic: A Dividend Aristocrat With Stability and InnovationWingstop Stock Jumps on Q1 Beat, Expansion OutlookBy Jeffrey Neal Johnson | May 4, 2025View Wingstop Stock Jumps on Q1 Beat, Expansion OutlookStrategists Say Hold: Stocks May Beat the 'Sell in May' TrendBy Jeffrey Neal Johnson | May 9, 2025View Strategists Say Hold: Stocks May Beat the 'Sell in May' TrendTBPH, TYRA, DYN, and AMRN Company DescriptionsAmarin NASDAQ:AMRN$10.42 +0.01 (+0.10%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$10.29 -0.13 (-1.24%) As of 04:21 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland.Dyne Therapeutics NASDAQ:DYN$12.56 +1.15 (+10.08%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$12.75 +0.19 (+1.51%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.Theravance Biopharma NASDAQ:TBPH$8.80 -0.18 (-2.00%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$8.80 +0.00 (+0.06%) As of 05/12/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.Tyra Biosciences NASDAQ:TYRA$10.26 +0.17 (+1.68%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$10.24 -0.02 (-0.15%) As of 04:25 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
